Topoisomerase I Inhibitors
"Topoisomerase I Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the activity of DNA TOPOISOMERASE I.
| Descriptor ID |
D059004
|
| MeSH Number(s) |
D27.505.519.389.892.500 D27.505.954.248.794.500
|
| Concept/Terms |
Topoisomerase I Inhibitors- Topoisomerase I Inhibitors
- Inhibitors, Topoisomerase I
- Topoisomerase 1 Inhibitors
- Inhibitors, Topoisomerase 1
- DNA Topoisomerase I Inhibitors
- DNA Type 1 Topoisomerase Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Topoisomerase I Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Topoisomerase I Inhibitors".
This graph shows the total number of publications written about "Topoisomerase I Inhibitors" by people in this website by year, and whether "Topoisomerase I Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2004 | 2 | 1 | 3 |
| 2006 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Topoisomerase I Inhibitors" by people in Profiles.
-
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. AAPS J. 2020 03 17; 22(3):59.
-
Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Oncotarget. 2017 Jul 04; 8(27):43733-43751.
-
Synthesizing topological structures containing RNA. Nat Commun. 2017 03 31; 8:14936.
-
Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIa catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells. Eur J Med Chem. 2017 Jan 05; 125:49-67.
-
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84.
-
Genistein sensitizes bladder cancer cells to HCPT treatment in vitro and in vivo via ATM/NF-?B/IKK pathway-induced apoptosis. PLoS One. 2013; 8(1):e50175.
-
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Nov 20; 29(33):4351-7.
-
Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm. 2011 Sep; 79(1):181-8.
-
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14.
-
[Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo]. Yao Xue Xue Bao. 2008 Aug; 43(8):811-8.